{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T11:38:30Z","timestamp":1774438710644,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"43","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008810","name":"NSW Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008810","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["APP1116530"],"award-info":[{"award-number":["APP1116530"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.vaccine.2022.09.029","type":"journal-article","created":{"date-parts":[[2022,9,21]],"date-time":"2022-09-21T04:50:12Z","timestamp":1663735812000},"page":"6288-6294","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection"],"prefix":"10.1016","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0787-5825","authenticated-orcid":false,"given":"Bette","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7595-9281","authenticated-orcid":false,"given":"Heather","family":"Gidding","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Stepien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Cretikos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4675-0232","authenticated-orcid":false,"given":"Kristine","family":"Macartney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.09.029_b0005","unstructured":"https:\/\/www.who.int\/news\/item\/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern."},{"key":"10.1016\/j.vaccine.2022.09.029_b0010","article-title":"Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa","author":"Collie","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.029_b0015","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/s41586-021-04388-0","article-title":"Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2","volume":"602","author":"Liu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2022.09.029_b0020","first-page":"2021","article-title":"New Omicron case confirmed in NSW","volume":"2","author":"NSW Health Media Release","year":"2021","journal-title":"Date"},{"key":"10.1016\/j.vaccine.2022.09.029_b0025","unstructured":"https:\/\/www.health.gov.au\/health-alerts\/covid-19\/case-numbers-and-statistics."},{"key":"10.1016\/j.vaccine.2022.09.029_b0030","doi-asserted-by":"crossref","unstructured":"Vette K, Machalek D, Gidding H, et al. Seroprevalence of SARS-CoV-2-specific antibodies in Australia following the first epidemic wave in 2020: a national survey. The Journal of infectious diseases 2022;In press (accepted Jan 2022).","DOI":"10.1093\/ofid\/ofac002"},{"key":"10.1016\/j.vaccine.2022.09.029_b0035","unstructured":"Australian Government Operation COVID Shield. COVID-19 vaccine rollout update - 23 November 2021. 2021."},{"key":"10.1016\/j.vaccine.2022.09.029_b0040","unstructured":"https:\/\/www.ncirs.org.au\/sites\/default\/files\/2022-02\/COVID-19-history-February%202022_0.pdf."},{"key":"10.1016\/j.vaccine.2022.09.029_b0045","article-title":"Coronavirus Pandemic (COVID-19)","author":"Ritchie","year":"2021","journal-title":"OurWorldInDataorg"},{"key":"10.1016\/j.vaccine.2022.09.029_b0050","unstructured":"https:\/\/view-hub.org\/covid-19\/effectiveness-studies."},{"key":"10.1016\/j.vaccine.2022.09.029_b0055","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection","volume":"386","author":"Hall","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.029_b0060","unstructured":"https:\/\/www.health.nsw.gov.au\/Infectious\/covid-19\/Documents\/covid-19-surveillance-report-20211120.pdf."},{"key":"10.1016\/j.vaccine.2022.09.029_b0065","unstructured":"https:\/\/ourworldindata.org\/explorers\/coronavirus-data-explorer?facet=none&Interval=7-day+rolling+average&Relative+to+Population=true&Color+by+test+positivity=false&country=\u223cAUS&Metric=Omicron+variant+%28share%29."},{"key":"10.1016\/j.vaccine.2022.09.029_b0070","unstructured":"https:\/\/www.abs.gov.au\/websitedbs\/censushome.nsf\/home\/seifa."},{"key":"10.1016\/j.vaccine.2022.09.029_b0075","unstructured":"https:\/\/www.health.nsw.gov.au\/Infectious\/covid-19\/Documents\/in-focus\/covid-19-vaccination-case-surveillance-051121.pdf."},{"key":"10.1016\/j.vaccine.2022.09.029_b0080","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2009.03.012","article-title":"Absolute risk reductions and numbers needed to treat can be obtained from adjusted survival models for time-to-event outcomes","volume":"63","author":"Austin","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.vaccine.2022.09.029_b0085","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1056\/NEJMoa2201570","article-title":"Protection by a Fourth Dose of BNT162b2 against Omicron in Israel","volume":"386","author":"Bar-On","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.029_b0090","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa2119451","article-title":"Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant","volume":"386","author":"Andrews","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.029_b0095","doi-asserted-by":"crossref","unstructured":"Buchan SA, Chung H, Brown KA, et al. Effectiveness of COVID-19 vaccines against Omicron or Delta infection. medRxiv 2022:2021.12.30.21268565.","DOI":"10.1101\/2021.12.30.21268565"},{"key":"10.1016\/j.vaccine.2022.09.029_b0100","doi-asserted-by":"crossref","unstructured":"Hansen CH, Schelde AB, Moustsen-Helm IR, et al. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv 2021:2021.12.20.21267966.","DOI":"10.1101\/2021.12.20.21267966"},{"key":"10.1016\/j.vaccine.2022.09.029_b0105","doi-asserted-by":"crossref","DOI":"10.1016\/S1473-3099(22)00141-4","article-title":"Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design","author":"Sheikh","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.029_b0110","doi-asserted-by":"crossref","unstructured":"Chemaitelly H, Ayoub HH, AlMukdad S, et al. Duration of mRNA vaccine protection against SARS-CoV-2 Omicron BA.1 and BA.2 subvariants in Qatar. medRxiv 2022:2022.03.13.22272308.","DOI":"10.1038\/s41467-022-30895-3"},{"key":"10.1016\/j.vaccine.2022.09.029_b0115","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1056\/NEJMc2200133","article-title":"Protection against the Omicron Variant from Previous SARS-CoV-2 Infection","volume":"386","author":"Altarawneh","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2022.09.029_b0120","doi-asserted-by":"crossref","first-page":"2200250","DOI":"10.2807\/1560-7917.ES.2022.27.16.2200250","article-title":"Vaccine-induced and naturally-acquired protection against Omicron and Delta symptomatic infection and severe COVID-19 outcomes, France, December 2021 to January 2022","volume":"27","author":"Suarez Castillo","year":"2022","journal-title":"Eurosurveillance"},{"key":"10.1016\/j.vaccine.2022.09.029_b0125","doi-asserted-by":"crossref","unstructured":"Cerqueira-Silva T, Shah SA, Robertson C, et al. Waning of mRNA Boosters after Homologous Primary Series with BNT162b2 or ChadOx1 Against Symptomatic Infection and Severe COVID-19 in Brazil and Scotland: A Test-Negative Design Case-Control Study. . http:\/\/dxdoiorg\/102139\/ssrn4082927 2022.","DOI":"10.2139\/ssrn.4082927"},{"key":"10.1016\/j.vaccine.2022.09.029_b0130","unstructured":"Chen Y, Tong P, Whiteman N, et al. Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Science Immunology;0:eabp8328."},{"key":"10.1016\/j.vaccine.2022.09.029_b0135","doi-asserted-by":"crossref","unstructured":"Bates TA, McBride SK, Leier HC, et al. Vaccination before or after SARS-CoV-2 infection leads to robust humoral response and antibodies that effectively neutralize variants. Science Immunology 2022;7:eabn8014.","DOI":"10.1126\/sciimmunol.abn8014"},{"key":"10.1016\/j.vaccine.2022.09.029_b0140","unstructured":"https:\/\/www.who.int\/news\/item\/01-06-2022-interim-statement-on-hybrid-immunity-and-increasing-population-seroprevalence-rates."},{"key":"10.1016\/j.vaccine.2022.09.029_b0145","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1016\/j.vaccine.2022.04.069","article-title":"Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization","volume":"40","author":"Feikin","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.029_b0150","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1186\/s12879-021-06378-z","article-title":"High risk groups for severe COVID-19 in a whole of population cohort in Australia","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.029_b0155","unstructured":"https:\/\/www.health.nsw.gov.au\/Infectious\/covid-19\/Documents\/covid-19-surveillance-report-20220201.pdf."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011264?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011264?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:19:09Z","timestamp":1759403949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22011264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":31,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0264410X22011264"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.029","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Relative effectiveness of COVID-19 vaccination with 3 compared to 2 doses against SARS-CoV-2 B.1.1.529 (Omicron) among an Australian population with low prior rates of SARS-CoV-2 infection","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}